Status:

COMPLETED

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

Lead Sponsor:

Cedars-Sinai Medical Center

Conditions:

Pituitary Adenomas

Prolactinomas

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This study focuses on new therapies for a challenging disease in pituitary medicine, that of aggressive pituitary tumors which have limited therapeutic options beyond standard surgical, radiotherapy, ...

Detailed Description

PURPOSE The drug Lapatinib has been shown to inhibit both epidermal growth factor receptor (EGFR) and erbB2 tyrosine kinases resulting in an effective slowing of disease progression in breast cancer....

Eligibility Criteria

Inclusion

  • Patients with nonfunctioning adenomas who have undergone at least one prior surgical resection and have demonstrated recurrence on MRI
  • Patients with prolactinomas who are resistant to dopamine agonist therapy
  • Patients with malignant pituitary tumors
  • Patients with visual field deficits and/or compression of the optic chiasm must be stable for at least 6 months

Exclusion

  • Patients with compromised visual fields and/or compression of the optic chiasm on MRI that has not been stable for last 6 months.
  • Patients that have reduced left ventricular ejection fraction less than 50%
  • Patients with moderate to severe hepatic impairment
  • Patients that are pregnant or lactating
  • Patients under the age of 18
  • Active hepatitis
  • Known previous HIV Positive
  • Concurrent cancers
  • Life expectancy less than one year

Key Trial Info

Start Date :

July 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2018

Estimated Enrollment :

9 Patients enrolled

Trial Details

Trial ID

NCT00939523

Start Date

July 1 2009

End Date

December 1 2018

Last Update

January 22 2020

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Cedars-Sinai Medical Center

Los Angeles, California, United States, 90048

2

Johns Hopkins University

Baltimore, Maryland, United States, 21287

3

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114